Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iclepertin in Schizophrenia (CONNEX-3)
NCT04860830Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Aug 2021
- Primary completion
- Oct 2024
- Countries
- 18
01
Overview
A Phase 3 trial of iclepertin in schizophrenia, sponsored by Boehringer Ingelheim. Started Aug 2021; status: completed.
02
Drugs
iclepertin
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT04860830.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04860830.